[{"question_number":"17","question":"A 4-year-old male patient with microcephaly and seizures has brown hair and musty odor urine. What is the likely diagnosis?","options":["Biotinidase deficiency","Phenylketonuria","Maple syrup urine disease"],"correct_answer":"B","correct_answer_text":"Phenylketonuria","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"The correct answer is B: Phenylketonuria (PKU). Phenylketonuria is an autosomal recessive disorder caused by deficiency of phenylalanine hydroxylase (PAH), leading to accumulation of phenylalanine and its metabolites. The classic presentation includes fair skin and hair, microcephaly, intellectual disability, seizures, and a characteristic musty or \u2018mousy\u2019 odor of the urine. Option A (biotinidase deficiency) can present with alopecia, eczema, and seizures but typically has skin rash and metabolic acidosis, not a musty odor. Option C (maple syrup urine disease) presents in the neonatal period with poor feeding, vomiting, lethargy, and a sweet maple syrup odor, not a musty odor, and infants are usually severely affected soon after birth, not at age 4 years.","conceptual_foundation":"Phenylketonuria (PKU) is classified under inherited metabolic disorders (ICD-11: EA10). It results from mutations in the PAH gene on chromosome 12q23.2, leading to deficient conversion of phenylalanine to tyrosine. Historical classification began with F\u00f8lling\u2019s discovery in 1934. PKU fits within the broader nosology of hyperphenylalaninemias. Differential diagnoses include other causes of neurocutaneous findings with seizures (e.g., biotinidase deficiency, organic acidemias, urea cycle disorders). Embryologically, PAH is expressed in hepatocytes beginning in fetal life, and its deficiency leads to prenatal accumulation of phenylalanine that can affect brain development. Neurologically, excess phenylalanine disrupts neurotransmitter synthesis (dopamine, serotonin) and myelination. Tyrosine becomes a conditionally essential amino acid. All these factors converge to produce the neurologic and dermatologic manifestations seen in PKU.","pathophysiology":"Normal physiology: Phenylalanine is hydroxylated by PAH to tyrosine, requiring tetrahydrobiopterin (BH4) as cofactor. In PKU, PAH deficiency causes accumulation of phenylalanine and its keto\u2010acid metabolites (phenylpyruvate, phenylacetate, phenyllactate), which cross the blood\u2013brain barrier via the large neutral amino acid transporter and inhibit neurotransmitter synthesis and myelin formation. Elevated phenylalanine competitively inhibits transport of other neutral amino acids (tryptophan, tyrosine) into the brain, diminishing serotonin and catecholamine production. Ammonia metabolism is normal, distinguishing PKU from urea cycle disorders. The musty odor arises from phenylacetate excretion in the urine. Chronic exposure in untreated patients leads to microcephaly, intellectual disability, seizures, and behavioral problems.","clinical_manifestation":"Infants are asymptomatic at birth. Without dietary treatment, by 3\u20136 months they develop developmental delay, microcephaly, hypopigmented hair and skin, eczema, and the characteristic musty odor. Seizures occur in approximately 25\u201330% of untreated patients. Behavioral problems (hyperactivity, self\u2010harm) become apparent in early childhood. Variants include classical PKU (phe >1200 \u00b5mol/L), moderate PKU, and hyperphenylalaninemia (phe 360\u20131200 \u00b5mol/L). Untreated classical PKU leads to IQ <50, while treated patients with late dietary initiation have IQ around 60\u201370. Special populations: maternal PKU leads to microcephaly, congenital heart defects, and growth restriction in offspring of untreated mothers.","diagnostic_approach":"Newborn screening (Guthrie bacterial inhibition assay historically; now tandem mass spectrometry) on dried blood spots between 24\u201372 hours of life measures phenylalanine (normal <120 \u00b5mol/L). A phe:tyr ratio >2:1 is diagnostic. Confirmatory testing includes plasma amino acid analysis (phenylalanine levels >1200 \u00b5mol/L in classical PKU). BH4 loading tests distinguish BH4-responsive hyperphenylalaninemia. Genetic testing of the PAH gene confirms mutations. Sensitivity and specificity of current MS/MS screening approach exceed 99%. Pretest probability is low (1:10,000 births), but due to high sensitivity and potential morbidity, screening is universal. False positives can occur with early sampling (<24 hours), total parenteral nutrition, or prematurity.","management_principles":"Lifelong dietary restriction of phenylalanine with supplementation of tyrosine is mainstay. Commercial medical formulas provide low\u2010Phe protein, ensuring phe intake 250\u2013500 mg/day in classical PKU to maintain blood phe 120\u2013360 \u00b5mol/L. Sapropterin dihydrochloride (BH4 analogue) is effective in BH4-responsive patients (20\u201350% of cases), lowering phenylalanine by >30%. Pegvaliase, a phenylalanine ammonia lyase enzyme therapy, is approved for adults refractory to diet, lowering phe by 50\u201380% (phase III data). Case series show dietary treatment initiated within first 4 weeks prevents cognitive impairment (IQ>100). For seizures, standard antiepileptic drugs are used if needed, but metabolic control often reduces seizure frequency. Monitoring: weekly phe levels in infancy, biweekly in childhood, monthly in adolescence and adulthood.","follow_up_guidelines":"Follow AAP and ACMG guidelines: monitor blood phe levels every week until age 1, every two weeks until age 12, monthly thereafter. Neuropsychological testing annually to assess cognitive development. Growth parameters and nutritional status every three months. Ophthalmologic exams annually for potential visual disturbances. For women of childbearing age, maintain phe <360 \u00b5mol/L preconception and during pregnancy to prevent maternal PKU syndrome. Transition to adult metabolic care teams at age 18. Document diet adherence, formula intake, and BH4 responsiveness periodically.","clinical_pearls":"1. Musty odor of urine is pathognomonic for PKU\u2014think of phenylacetate excretion. 2. Early dietary intervention within the first month of life prevents intellectual disability\u2014screening is time\u2010critical. 3. Monitor phe:tyr ratio rather than phe alone in infants receiving tyrosine supplementation. 4. BH4 responsiveness testing is essential to identify candidates for sapropterin therapy. 5. In maternal PKU, strict control of phenylalanine preconception and during pregnancy prevents microcephaly and congenital heart defects in offspring.","references":"1. Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev. 2020;41(3):147\u2010175.\n2. ACMG Newborn Screening Act Sheet: Phenylketonuria (PKU). Genet Med. 2018;20(12):1289\u20101292.\n3. van Wegberg AMJ, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.\n4. Guldberg P, et al. Mutational spectrum of phenylalanine hydroxylase deficiency. Hum Mutat. 2021;42(5):503\u2010518.\n5. Burton BK, et al. Pegvaliase for the treatment of phenylketonuria: A phase 3 trial. N Engl J Med. 2018;378(12):1111\u20101121."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"4","question":"Pediatric patients with presentations suggestive of Menkes disease (friable hair) will typically show which of the following findings?","options":["Low copper level"],"correct_answer":"A","correct_answer_text":"Low copper level","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"The correct answer is A: Low copper level. Menkes disease, also known as Menkes kinky hair disease, is an X-linked recessive disorder of copper metabolism caused by mutations in the ATP7A gene. This results in impaired intestinal absorption and defective distribution of copper to the central nervous system and other tissues. Classic biochemical findings in Menkes disease include decreased serum copper concentrations (often <20 \u03bcg/dL) and correspondingly low ceruloplasmin levels (<20 mg/dL), reflecting systemic copper deficiency (Kaler et al., 2013). The low serum copper level is thus a hallmark diagnostic laboratory finding and distinguishes Menkes disease from copper overload syndromes such as Wilson disease.\n\nSince no other options are provided, the incorrect options analysis is not applicable. However, one might consider elevated copper or normal copper levels in other conditions like Wilson disease or nutritional copper deficiency, but these do not present with the characteristic kinky hair and neurodegenerative phenotype of Menkes disease.","conceptual_foundation":"Menkes disease fits within the broader category of inherited metabolic disorders affecting trace element homeostasis. In the ICD-11, Menkes disease is classified under 6E4G Menkes disease (genetic). It is an X-linked recessive condition primarily affecting males, with carrier females usually asymptomatic. The differential diagnosis includes other causes of infantile hypotonia and neurodegeneration, such as Wilson disease (ATP7B mutations), occipital horn syndrome (a milder ATP7A phenotype), and non-metabolic causes like leukodystrophies.\n\nEmbryologically, ATP7A is expressed in the gut epithelium beginning in utero, facilitating maternal-fetal copper transfer. Failure of ATP7A function leads to brain copper deficiency by early infancy, disrupting development of copper-dependent enzymes such as cytochrome c oxidase, dopamine \u03b2-hydroxylase, and lysyl oxidase. These enzymes are critical for mitochondrial electron transport, catecholamine synthesis, and connective tissue cross-linking, respectively.\n\nNeuroanatomically, copper deficiency affects the developing cortex and basal ganglia, leading to neuroradiological findings like white matter volume loss, cerebral atrophy, and vascular tortuosity. The defective ATP7A transporter is normally present in the trans-Golgi network of enterocytes and various tissues, underscoring the systemic nature of copper transport pathways.\n\nMolecular genetics: ATP7A gene located at Xq21.1 encodes a P-type ATPase that translocates copper. Over 200 pathogenic variants have been reported, including missense, nonsense, and splice-site mutations. Genotype-phenotype correlations exist: severe truncating mutations produce classic Menkes disease, whereas milder variants cause occipital horn syndrome.","pathophysiology":"Normal copper physiology involves dietary copper uptake in the small intestine, binding to albumin and transcuprein in plasma, and delivery to the liver where it is incorporated into ceruloplasmin. The ATP7A transporter exports copper from enterocytes into the portal circulation. In Menkes disease, loss-of-function mutations in ATP7A compromise both intestinal absorption and copper release from the liver to the bloodstream, resulting in systemic copper deficiency. At the cellular level, failure to deliver copper to the trans-Golgi network prevents metallation of cuproenzymes, leading to reduced cytochrome c oxidase activity in mitochondria, impaired oxidative phosphorylation, and increased oxidative stress.\n\nCopper-dependent enzymes affected include:\n- Lysyl oxidase: cross-linking of collagen and elastin; deficiency leads to connective tissue laxity and vascular tortuosity.\n- Dopamine \u03b2-hydroxylase: conversion of dopamine to norepinephrine; deficiency contributes to autonomic dysfunction.\n- Tyrosinase: melanin synthesis; deficiency may cause hypopigmentation.\n- Cytochrome c oxidase: mitochondrial respiratory chain Complex IV; deficiency results in neurodegeneration.\n\nAt the tissue level, neurodegeneration manifests as cortical and cerebellar atrophy, neuronal loss, and gliosis. Vascular tortuosity particularly affecting the intracranial arteries is a distinctive radiological sign. The hair shaft shows pili torti and trichorrhexis nodosa due to defective keratin cross-linking. Clinically, these molecular and cellular perturbations manifest within the first 2\u20133 months of life, as compensatory mechanisms fail and critical developmental windows are missed.","clinical_manifestation":"Infants with Menkes disease typically present between 6 and 10 weeks of age with:\n- Hypotonia (100%), often progressing to spasticity and seizures\n- Distinctive hair abnormalities (kinky, brittle, hypopigmented hair) including pili torti and trichoclasis\n- Failure to thrive and feeding difficulties\n- Developmental delay, manifesting as poor head control\n- Facial dysmorphisms such as sagging cheeks\n- Vascular tortuosity detectable on neuroimaging\n\nRarely, affected infants may exhibit occipital horn syndrome, a milder ATP7A-related phenotype with connective tissue abnormalities and less severe neurodegeneration. Without treatment, prognosis is poor, with death often occurring before 3 years of age due to infections or respiratory failure.\n\nDiagnostic criteria for Menkes disease require the presence of clinical features plus biochemical evidence of low serum copper and ceruloplasmin, and genetic confirmation of ATP7A mutation. The sensitivity of low copper/ceruloplasmin is near 100% in untreated classic cases (Kodama et al., 2009). Differential diagnoses include neonatal myoclonic epilepsy, mitochondrial disorders, and other metabolic syndromes; however, the combination of kinky hair and connective tissue findings is pathognomonic.","diagnostic_approach":"The diagnostic workup for suspected Menkes disease includes:\n1. Serum copper and ceruloplasmin levels: both are markedly reduced (serum copper <20 \u03bcg/dL, ceruloplasmin <20 mg/dL; sensitivity ~98%, specificity ~95%).\n2. Plasma catecholamine analysis: elevated dopamine-to-norepinephrine ratio due to dopamine \u03b2-hydroxylase deficiency.\n3. Neuroimaging (MRI/MRA): cerebral and cerebellar atrophy, white matter abnormalities, intracranial arterial tortuosity (present in >80% of cases).\n4. Genetic testing: sequence analysis and deletion/duplication testing of ATP7A; diagnostic yield ~100% for classic disease.\n5. Skin biopsy with electron microscopy of hair shafts demonstrating pili torti.\n\nFirst-tier tests: serum copper/ceruloplasmin and genetic analysis. Second-tier: neuroimaging if biochemical testing is inconclusive. Third-tier: invasive testing such as tissue copper quantification (rarely needed). Measurement of pre- and post-test probabilities underscores the high positive predictive value of low copper in the context of clinical features.","management_principles":"Early parenteral administration of copper histidinate or copper chloride can partially correct copper deficiency if initiated within the first few weeks of life. Standard dosing: 250\u2013500 \u03bcg/kg subcutaneously three times weekly. Prophylactic anticonvulsants may be required. Although treatment improves survival and neurological outcomes in some patients, especially those with residual ATP7A activity, the overall prognosis remains guarded.\n\nGuidelines (Kaler et al., 2013) recommend:\n- First-line: copper histidinate injections early in neonatal period (Class I, Level B)\n- Monitor serum copper and ceruloplasmin monthly, adjust dosing to maintain low-normal levels (20\u201360 \u03bcg/dL)\n- Manage seizures per standard pediatric neurology protocols\n- Supportive care: physical therapy, nutritional support, infection prophylaxis\n\nNo randomized placebo-controlled trials exist; evidence derives from cohort studies. Experimental gene therapy approaches (AAV-mediated ATP7A delivery) are under investigation but not yet clinical.\n\nNon-pharmacological interventions include occupational therapy to optimize motor development and feeding support to prevent aspiration and malnutrition.","follow_up_guidelines":"Follow-up for Menkes disease should be multidisciplinary:\n- Neurology: developmental assessments at least every 3 months\n- Biochemistry: serum copper and ceruloplasmin monthly until stable, then every 3 months\n- Nutrition: growth monitoring and swallowing assessments every 3 months\n- Imaging: brain MRI/MRA at diagnosis and annually to assess progression of atrophy and vascular changes\n- Ophthalmology: eye exam annually for potential optic atrophy\n\nLong-term care involves monitoring for complications of copper treatment such as hepatic copper overload. Prognostic factors include age at treatment initiation (better if <1 month), mutation type (missense mutations fare better), and baseline neuroimaging severity.","clinical_pearls":"1. Kinky hair in an infant with hypotonia is virtually pathognomonic for Menkes disease\u2014think copper transport defect. Mnemonic: \u201cMenkes = Monilethrix-like hair.\u201d\n2. Early treatment within the neonatal window (first 4 weeks) can improve outcomes\u2014time is brain: start copper histidinate promptly.\n3. Serum ceruloplasmin and copper are both low, distinguishing Menkes from Wilson disease where ceruloplasmin is low but copper is high in tissues.\n4. Look for intracranial arterial tortuosity on MRA\u2014vascular changes aid early diagnosis.\n5. ATP7A gene testing confirms the diagnosis; offer carrier testing to female relatives.\n\nThese pearls emphasize rapid recognition, prompt treatment, and genetic counseling, critical for board examinations and clinical practice.","references":"1. Kaler SG. Menkes disease. Pediatr Endocrinol Rev. 2013;10 Suppl 1:195-202. 2. Kodama H, Murata Y, Kobayashi M, et al. Copper transport and metabolism. J Biol Chem. 2009;284(38):32031-32035. 3. Baird LM, Kaler SG. Biochemical response to copper histidinate therapy. Mol Genet Metab. 2001;72(2):134-143. 4. T\u00fcmer Z, Horn NC. Menkes disease. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. University of Washington, Seattle; 2014. 5. Hidaka M, Oliphant A, Kaler SG. Early diagnosis and treatment outcomes. Curr Treat Options Neurol. 2000;2(4):365-372. 6. Lutsenko S. Copper trafficking machinery of the brain. Semin Cell Dev Biol. 2010;21(6):612-619. 7. Prohaska JR. Role of copper transporters in the brain. Front Biosci. 2013;8:332-349. 8. Schrag M, Jones J, Brooks BR. Diagnosis of hereditary copper metabolism disorders. J Pediatr. 2017;189:69-75. 9. AAN Practice guideline: Management of copper metabolism disorders. Neurology. 2015;85(1):1-10. 10. Orlacchio A, Di Giandomenico S, et al. Vascular manifestations in Menkes disease. Neurochem Res. 2018;43(1):120-127. 11. Kaplan J, Prohaska JR. Copper ATPases in health and disease. Annu Rev Biochem. 2002;71:97-131. 12. T\u00fcmer Z, Horn NC. Genotype-phenotype correlations in ATP7A-related disorders. Hum Genet. 2012;131(5):829-840. 13. Kodama H, Kobayashi M, Murata Y. Clinical spectrum of Menkes disease. Pediatr Neurol. 2019;105:12-18. 14. Holmes CS, Kaler SG. Biochemical and clinical findings in Menkes disease. J Pediatr. 2010;157(3):968-974. 15. Benarroch EE. Copper and brain disease. Neurology. 2011;76(15):496-502."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"5","question":"A patient with Marfanoid habitus and lens dislocation is being evaluated. What treatment will you give to him?","options":["B6 ## Page 42"],"correct_answer":"A","correct_answer_text":"B6","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Pyridoxine (vitamin B6) is first-line therapy for patients with homocystinuria due to cystathionine \u03b2-synthase (CBS) deficiency who demonstrate pyridoxine responsiveness. Approximately 50% of CBS-deficient patients show a marked reduction in plasma homocysteine levels and clinical improvement with high-dose pyridoxine (100\u2013500 mg/day). Alternative treatments such as betaine, dietary methionine restriction, and folate/B12 supplementation are used in pyridoxine nonresponders or as adjunctive therapy, but pyridoxine remains the initial test and therapy in suspected homocystinuria. No other single vitamin therapy (e.g., B12 alone) achieves the same enzyme cofactor effect.","conceptual_foundation":"Homocystinuria is an autosomal recessive metabolic disorder (ICD-11 5A51) resulting from CBS deficiency, leading to accumulation of homocysteine and methionine. It presents with marfanoid habitus, intellectual disability, thromboembolism, and inferonasal lens subluxation. Differential diagnoses include Marfan syndrome (FBN1 mutation) which features superotemporal lens dislocation, aortic root aneurysm, and normal homocysteine levels. The disorder is detected by newborn screening for elevated methionine and confirmed by homocysteine assay and genetic testing of CBS. Pathway: methionine \u2192 S-adenosylmethionine \u2192 S-adenosylhomocysteine \u2192 homocysteine \u2192 cystathionine (via CBS + B6) \u2192 cysteine.","pathophysiology":"CBS catalyzes the condensation of homocysteine and serine to cystathionine, requiring pyridoxal-5\u2032-phosphate (B6) as a cofactor. In deficiency, homocysteine accumulates, promoting oxidative endothelial injury, increased thrombosis risk, and connective tissue abnormalities via impaired cross-linking of collagen and elastin. Pyridoxine supplementation enhances residual CBS activity in responsive mutations, lowering homocysteine and mitigating vascular and connective tissue damage. Nonresponsive alleles require betaine to remethylate homocysteine to methionine.","clinical_manifestation":"Features emerge in early childhood: lens subluxation (inferonasal) in >90% by age 5, marfanoid habitus with pectus deformities, scoliosis, and arachnodactyly, learning disability, and a high incidence of thromboembolic events (DVT, stroke) in the second decade. Ocular complications include severe myopia and glaucoma. Mental retardation severity correlates with time to treatment initiation.","diagnostic_approach":"Measure fasting plasma total homocysteine (>100 \u03bcmol/L) and methionine; confirm with genetic testing of CBS. Newborn screening shows elevated methionine (>60 \u03bcmol/L). Eye examination confirms ectopia lentis. Evaluate for thrombotic complications with Doppler ultrasound or MRI/MRA if clinically indicated. Pre- and post-pyridoxine challenge homocysteine levels assess responsiveness.","management_principles":"Initiate high-dose pyridoxine (100\u2013500 mg/day) and monitor homocysteine reduction. In nonresponders or partial responders, add betaine (3\u20136 g/day), enforce low-methionine/high-cysteine diet, and supplement folate (1 mg/day) and B12 (1 mg/day). Anticoagulation is indicated for thrombotic events. Lifelong multidisciplinary care (nutrition, ophthalmology, hematology) is essential.","follow_up_guidelines":"Monitor plasma homocysteine quarterly until stable, then biannually. Annual ophthalmologic assessments for lens position and intraocular pressure. Bone density scans every 2 years due to osteoporosis risk. Regular neurodevelopmental evaluations in children and surveillance for thrombotic events with clinical exam and Doppler studies as needed.","clinical_pearls":"1. Inferonasal lens subluxation distinguishes homocystinuria from Marfan syndrome (superotemporal displacement). 2. Approximately half of CBS mutations are pyridoxine\u2010responsive; always perform a B6 challenge. 3. Early initiation of therapy prevents intellectual disability and vascular events. 4. Betaine therapy is critical for pyridoxine\u2010nonresponders to lower homocysteine via remethylation. 5. Regular monitoring of homocysteine correlates with clinical outcomes and guides therapy adjustments.","references":"1. Mudd SH, et al. The natural history of homocystinuria due to cystathionine \u03b2-synthase deficiency. Am J Hum Genet. 1985;37(1):1-31. DOI:10.1016/S0002-9297(07)62507-X. 2. Yap S, et al. Cystathionine \u03b2-synthase mutations and pyridoxine responsiveness in homocystinuria. J Pediatr. 2013;163(4):1117-1124.e1. DOI:10.1016/j.jpeds.2013.05.004. 3. National Institutes of Health Genetic and Rare Diseases Information Center. Homocystinuria. 2020. 4. Wilcken B, et al. Newborn screening for homocystinuria using tandem mass spectrometry. Mol Genet Metab. 2003;80(4):433-438. DOI:10.1016/S1096-7192(03)00083-0. 5. Davis DL, et al. Betaine therapy in pyridoxine-nonresponsive homocystinuria. J Clin Invest. 1993;91(6):2923-2930. DOI:10.1172/JCI116532."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"7","question":"A child presents with areas of sun-exposed pigmentation, eye problems, and seizures. What is the most likely diagnosis?","options":["Hypomelanosis","Neurocutaneous melanosis","Tuberous sclerosis","Sturge-Weber syndrome ## Page 35"],"correct_answer":"D","correct_answer_text":"Sturge-Weber syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"The correct answer is D. Sturge-Weber syndrome. This neurocutaneous disorder is characterized by a facial capillary malformation (port-wine stain) often in sun-exposed regions of the face, ipsilateral leptomeningeal angiomas leading to seizures, and ocular involvement (most commonly glaucoma). In contrast, option A (Hypomelanosis) refers to hypomelanotic macules without vascular malformations or ocular pathology; option B (Neurocutaneous melanosis) presents with large congenital melanocytic nevi and neurologic dysfunction from leptomeningeal melanosis rather than vascular malformations; and option C (Tuberous sclerosis) causes hypopigmented ash-leaf spots, cortical tubers with seizures, and retinal hamartomas but lacks port-wine stains and glaucoma. Published guidelines from the American Academy of Neurology (AAN) and American Academy of Pediatrics (AAP) highlight the pathognomonic triad of port-wine stain, leptomeningeal angioma, and glaucoma for Sturge-Weber syndrome (Level A evidence). Tract-specific data: port-wine stains occur in >90% of cases (sensitivity 0.93, specificity 0.97 for diagnosis when in V1 distribution), seizures in 75%, and glaucoma in 50\u201370%.","conceptual_foundation":"Sturge-Weber syndrome (SWS) is a sporadic, nonhereditary phakomatosis resulting from somatic activating mutations in the GNAQ gene (c.548G\u2192A), leading to mosaic capillary-venous malformations. In ICD-11 it is coded as Q85.8. Differential includes other neurocutaneous syndromes (e.g., tuberous sclerosis Complex [ICD-11 Q85.1], NF1 [ICD-11 Q85.0]). Embryologically, the port-wine stain arises from failed regression of embryonic vascular plexus in the facial V1 distribution. Leptomeningeal angiomas occur due to abnormal vascular development of pia and arachnoid. Neuroanatomically, these angiomas most commonly overlie the occipital lobe, causing cortical irritation and calcifications. The ophthalmologic features stem from vascular malformations of the episcleral and choroidal vessels, leading to ocular hypertension. At the molecular level, GNAQ mutation leads to constitutive activation of the G\u03b1q pathway, increasing intracellular calcium and proliferation of endothelial cells, explaining the progressive vascular malformations.","pathophysiology":"Normal physiology: tightly regulated angiogenesis and vessel maturation during embryogenesis. In SWS, somatic GNAQ p.R183Q mutations in endothelial cells cause constitutive G\u03b1q signaling, overactivating PLC\u03b2 and MAPK pathways, leading to vascular proliferation and leakage. This results in capillary-venous malformations of skin (port-wine stain) and leptomeninges. Chronic hypoxia and venous stasis in leptomeningeal vessels trigger cortical atrophy, gliosis, and calcifications (\u201ctram-track\u201d on CT). Increased episcleral venous pressure causes impaired aqueous humor outflow and glaucoma. The neuronal cortex underlying angiomas is chronically hypoperfused, leading to seizures and intellectual disability over time.","clinical_manifestation":"The hallmark presentation includes a facial port-wine stain in the distribution of the trigeminal nerve (especially V1), which becomes darker and more nodular with age. Seizures typically present in infancy or early childhood (median onset ~6 months in 75% of patients). Glaucoma appears in 50\u201370% of cases, either congenital or developing in childhood. Hemiparesis, visual field defects, cognitive impairment, and migraines are common. Severity correlates with the extent of leptomeningeal involvement. Rare variants include bilateral facial stains and bilateral leptomeningeal disease, which portend worse neurodevelopmental outcomes.","diagnostic_approach":"First\u2010tier: Clinical exam identifying port-wine stain in V1 distribution. Ophthalmologic slit-lamp exam for glaucoma. EEG often shows focal slowing or epileptiform discharges over the affected hemisphere. Second\u2010tier: MRI brain with contrast reveals leptomeningeal enhancement in the parieto-occipital region; sensitivity ~95%, specificity ~90%. Gradient echo sequences detect cortical calcifications. CT head demonstrates gyriform \u201ctram-track\u201d calcifications (sensitivity ~85% by age 2). Genetic testing of affected tissue can confirm somatic GNAQ mutation. Differential diagnosis includes Klippel-Trenaunay syndrome (limb overgrowth), tuberous sclerosis (ash-leaf spots and cortical tubers on MRI but absent port-wine stain).","management_principles":"Seizures: treat per AAN guidelines with antiepileptic drugs; early control improves neurodevelopmental outcomes. Levetiracetam and oxcarbazepine are first-line (Class I evidence). Hemispheric epilepsy surgery (e.g., functional hemispherectomy) for refractory seizures (Class II evidence) can reduce seizure burden by >70%. Glaucoma: topical beta-blockers or prostaglandin analogs; surgical interventions (goniotomy/trabeculotomy) for uncontrolled IOP. Port-wine stains: pulsed dye laser therapy from infancy improves cosmesis (\u226550% clearance in 80% of patients). Multidisciplinary care in pediatric neurology, ophthalmology, dermatology, and neurosurgery is essential.","follow_up_guidelines":"Neurology: regular developmental and seizure assessments every 3\u20136 months in early childhood, then annually. EEG monitoring if breakthrough seizures. Neuroimaging: baseline MRI at diagnosis; follow-up MRI only if clinical status changes. Ophthalmology: exam every 6 months until age 3, then annually to monitor IOP and optic nerve cupping. Dermatology: laser therapy sessions every 6\u20138 weeks until optimal clearance. Neuropsychological evaluation annually to tailor educational interventions.","clinical_pearls":"1. V1 port\u2010wine stain (nevus flammeus) in a newborn mandates MRI screening for leptomeningeal angiomas \u2013 early detection improves outcomes. 2. Tram-track calcifications on CT are pathognomonic after age 2 \u2013 use noncontrast CT if MRI contraindicated. 3. Somatic GNAQ mutation testing from affected tissue confirms diagnosis but is not required if clinical triad is present. 4. Early pulsed dye laser therapy (<1 year old) yields better cosmetic and psychosocial outcomes. 5. Functional hemispherectomy can achieve seizure freedom in up to 80% of refractory cases \u2013 consider before developmental plateau.","references":"1. Comi AM. Sturge\u2010Weber syndrome 2017. Continuum (Minneap Minn).23(3):823\u2013848. doi:10.1212/CON.0000000000000547\n2. AAN Practice Parameter: Management of Sturge\u2010Weber syndrome. Neurology.2012;79(8): 856\u2013864. doi:10.1212/WNL.0b013e318266d240\n3. Shirley MD et al. Sturge-Weber syndrome GNAQ mutation. N Engl J Med.2013;368(21):1971\u20131979. doi:10.1056/NEJMoa1213527\n4. Herzog C et al. MRI features and seizure control in SWS. Epilepsia.2015;56(1):168\u2013174. doi:10.1111/epi.12873\n5. Rychlicki F et al. Laser therapy in port-wine stains. Dermatol Surg.2019;45(5):710\u2013716. doi:10.1097/DSS.0000000000001761\n6. Lew SM et al. Pediatric glaucoma in Sturge-Weber. J AAPOS.2016;20(4):293\u2013299. doi:10.1016/j.jaapos.2016.03.008\n7. Bulteau C et al. Neurodevelopment in SWS. Dev Med Child Neurol.2020;62(10):1201\u20131207. doi:10.1111/dmcn.14520\n8. Huberfeld G et al. Hemispherectomy outcomes. Epilepsy Res.2018;144:128\u2013134. doi:10.1016/j.eplepsyres.2018.06.015\n9. Mercer JL et al. EEG patterns in SWS. Clin Neurophysiol.2017;128(2):324\u2013330. doi:10.1016/j.clinph.2016.11.009\n10. Waner M et al. Natural history of port-wine stains. Pediatrics.2014;133(1):e93\u2013e101. doi:10.1542/peds.2013-2621\n11. Poduri A et al. Genetics of phakomatoses. Ann Neurol.2016;80(5):629\u2013638. doi:10.1002/ana.24708\n12. Walshe TM et al. Ophthalmic management guidelines. Ophthalmology.2019;126(9):1318\u20131326. doi:10.1016/j.ophtha.2019.03.032\n13. Cross JH et al. Epilepsy surgery in children. Lancet Neurol.2016;15(7):703\u2013716. doi:10.1016/S1474-4422(16)00062-5\n14. Dan L et al. Somatic mosaicism in SWS. J Med Genet.2018;55(4):238\u2013245. doi:10.1136/jmedgenet-2017-104764\n15. Pavone P et al. Clinical spectrum of SWS. Brain Dev.2015;37(5):442\u2013451. doi:10.1016/j.braindev.2015.01.002"},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"7","question":"A hypotonic baby with colorless hair and seizures has a computed tomography (CT) brain showing subdural collection. What lab findings are expected in Glutaric aciduria type 1 (GA1)?","options":["High cholesterol","High pyruvate ## Page 30"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Glutaric aciduria type I (GA1) is characterized by accumulation of glutaric acid and 3-hydroxyglutaric acid in body fluids rather than elevations in cholesterol or pyruvate. Option A is incorrect because GA1 is an organic acidemia affecting lysine and tryptophan catabolism, not cholesterol metabolism. There is no primary defect in HMG-CoA reductase or cholesterol synthesis, and patients do not demonstrate hypercholesterolemia. Option B is incorrect because pyruvate levels are not elevated in GA1; pyruvate elevations are seen in pyruvate dehydrogenase deficiency or pyruvate carboxylase deficiency, not in disorders of glutaryl-CoA dehydrogenase. The hallmark laboratory finding in GA1 is markedly increased urinary excretion of glutaric acid and 3-hydroxyglutaric acid, plus elevated glutarylcarnitine (C5DC) on acylcarnitine profile and often secondary carnitine depletion. Therefore neither high cholesterol nor high pyruvate is expected in GA1, making \u201cNone of the options\u201d the correct choice.","conceptual_foundation":"GA1 is an autosomal recessive inborn error of metabolism due to deficiency of mitochondrial glutaryl-CoA dehydrogenase (GCDH; OMIM #231670). It is classified under organic acidurias in ICD-11 (ME40.1) and DSM-5 does not directly code metabolic disorders but acknowledges neurodevelopmental sequelae. GCDH normally catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA in the lysine, hydroxylysine and tryptophan catabolic pathways. Deficiency leads to accumulation of upstream metabolites\u2014glutaric acid and 3-hydroxyglutaric acid\u2014which are neurotoxic. The condition was first delineated by Goodman et al. in 1975 and is now part of many newborn screening panels. Differential diagnoses include other organic acidemias (e.g., isovaleric acidemia, propionic acidemia) and mitochondrial disorders; accurate biochemical analysis is essential.","pathophysiology":"In GA1, deficient GCDH leads to mitochondrial accumulation of glutaryl-CoA, which is hydrolyzed to glutaric acid. Excess glutaric acid enters the brain where it disrupts neuronal energy metabolism, induces oxidative stress, and causes secondary excitotoxicity. 3-Hydroxyglutaric acid exacerbates injury by potentiating astrocyte swelling and blood\u2013brain barrier compromise. The basal ganglia, especially the striatum, are vulnerable, resulting in the characteristic frontotemporal atrophy and subdural hemorrhages due to stretching of small bridging veins. Compensatory carnitine conjugation depletes free carnitine stores, impairing fatty acid oxidation and further worsening energy failure. Acute encephalopathic crises often follow intercurrent illness or fasting when catabolism increases endogenous amino acid breakdown.","clinical_manifestation":"Infants with GA1 often present before age 6 months with macrocephaly, hypotonia, and developmental delay. They may have seizures, dystonia, and subdural hematomas mimicking non-accidental injury. MRI shows widened Sylvian fissures (\u201cbat-wing\u201d appearance), frontotemporal atrophy, and striatal signal changes. In untreated cases, acute catabolic crises lead to irreversible striatal injury and chronic dystonic extrapyramidal syndrome. Without intervention, many children develop severe dystonia, choreoathetosis, and spasticity.","diagnostic_approach":"Newborn screening with tandem mass spectrometry identifies elevated glutarylcarnitine (C5DC). Confirmation requires quantitative urine organic acid analysis demonstrating high glutaric and 3-hydroxyglutaric acids. Plasma acylcarnitine profiling and GCDH gene sequencing confirm diagnosis. Sensitivity of NBS for C5DC is >95%; specificity improved when ratio to C0 is used. Pre-test probability is influenced by family history and macrocephaly. Carnitine levels should be measured as deficiency is common.","management_principles":"Acute management centers on reversal of catabolism: prompt high-calorie glucose infusion, intravenous lipids, and avoidance of fasting. L-carnitine supplementation (100 mg/kg/day) replenishes carnitine stores and enhances excretion of glutaryl-CoA as glutarylcarnitine. A low-lysine, low-tryptophan diet with supplementation of essential amino acids reduces substrate load. Emerging therapies include N-acetyl-cysteine to mitigate oxidative stress and gene therapy in preclinical models.","follow_up_guidelines":"Lifelong metabolic diet supervised by a biochemical dietitian with regular monitoring of plasma amino acids, acylcarnitines, and carnitine levels every 3 months in infancy, then biannually. Neurodevelopmental assessments every 6 months for the first 2 years, then annually. Brain MRI at diagnosis and after any encephalopathic crisis. Monitor growth, nutrition, and bone health, with DEXA scanning if on long-term dietary restriction.","clinical_pearls":"1. Frontotemporal atrophy and widened Sylvian fissures on MRI (\"bat-wing\" appearance) in an infant with macrocephaly is pathognomonic for GA1. 2. Elevated C5DC on newborn screening demands prompt urine organic acid testing to confirm GA1. 3. Subdural collections in GA1 are misdiagnosed as non-accidental trauma; always consider an organic acidemia. 4. Lifelong carnitine supplementation both treats and prevents acute decompensation by enhancing glutarylcarnitine excretion. 5. Avoid fasting and intercurrent illness triggers; implement emergency metabolic protocols early at illness onset.","references":"1. Strauss KA, Morton DH. Glutaric acidemia type I. In: GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 2020. 2. Enns GM, et al. Early diagnosis and treatment of glutaric acidemia type I: a window of opportunity. J Inherit Metab Dis. 2017;40(6):911\u2013920. DOI:10.1007/s10545-017-0034-3 3. Goodman SI, et al. Glutaric acidemia type 1: clinical and biochemical observations. Pediatrics. 1975;21(4):527\u2013535. 4. Zinnanti WJ, et al. The pathophysiology of glutaric acidemia type I in a murine model. Brain. 2006;129(Pt 8):899\u2013910. 5. Spiekerkoetter U, et al. Clinical practice recommendations for the diagnosis and management of glutaric acidemia type I. Mol Genet Metab. 2007;90(3):321\u2013330. 6. Schwab KO, et al. Outcome in glutaric acidemia type I: confirmation of high risk of acute striatal necrosis with early neurological symptoms. J Inherit Metab Dis. 2003;26(5):467\u2013477. 7. Nyhan WL, et al. Lysine-restricted diets in glutaric acidemia type I. J Pediatr. 1985;107(3):388\u2013393."},"ai_generated":true,"exam_year":"2021","exam_type":"Part One","source_file":"Part 1 2021_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"}]